VEGF-C

VEGF-C Overview

English NameVascular endothelial growth factor CApproved Drugs0
Drugs in Clinical Trials2Target SynonymLMPHM4,Vascular Endothelial Growth Factor-Related Protein,Flt4-L,VRP,FLT4 Ligand DHM,LMPH1D,VEGF-C,Vascular Endothelial Growth Factor C,Flt4 ligand,VEGFC
Highest Development StagePhase 2 Clinical
English NameVascular endothelial growth factor C
Target SynonymLMPHM4,Vascular Endothelial Growth Factor-Related Protein,Flt4-L,VRP,FLT4 Ligand DHM,LMPH1D,VEGF-C,Vascular Endothelial Growth Factor C,Flt4 ligand,VEGFC
Approved Drugs0
Drugs in Clinical Trials2
Highest Development StagePhase 2 Clinical

VEGF-C Product List

  • Product Category

    Protein (3)

  • Product Status

    Launched (3)

  • Species

    Human (1)Cynomolgus (1)Mouse (1)

  • Tag

    His Tag (1)His Tag & Avi Tag (2)

  • Conjugate

    Unconjugated (1)Biotin-labeled (2)

VEGF-C Background

Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

VEGF-C Synonyms

VEGFC,Flt4-L,VRP

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
VEGF-C gene therapy (Herantis Pharma)LX-1101; Ad-VEGF-CPhase 2 ClinicalHerantis PharmaLymphedema
Details
IBI-333IBI-333Phase 1 ClinicalMacular Degeneration; Wet Macular Degeneration
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호